Businesswire News Releases

Aug 12, 2022 01:45 ET
InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma in China
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) accepted a supplemental New Drug Application (sNDA) for Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment of patients with relapsed or refractory Marginal Zone Lymphoma (R/R MZL)....
Aug 12, 2022 01:00 ET
Disclosure of data on Agaricus blazei mushroom, KA21's immunity-enhancing mechanism, immunological enhancement effect confirmed by human clinical trials, and candida and other types of fungal infectio
On its website www.toeishinyaku.jp, Toei Shinyaku has disclosed data concerning the mechanism by which Agaricus blazei KA21 enhances immunity, its immunological enhancement effect as confirmed by human clinical trials, and candida and other types of fungal infection. Agaricus blazei KA21 product has been sold in the Japanese market a...
Aug 12, 2022 00:30 ET
Disclosure of data on effects of Agaricus blazei mushroom, KA21 strain for improvement of hair loss & gray hair in human clinical trials and promotion of hair growth in mice, Toei Shinyaku
On its website www.toeishinyaku.jp, Toei Shinyaku has disclosed data from human clinical trials concerning the effects of Agaricus blazei mushroom, KA21 strain for improvement of hair loss & gray hair, as well as its effects for promotion of hair growth in mice. Agaricus blazei mushroom, KA21 strain is being sold as a supplement with...
Aug 12, 2022 00:00 ET
Survey of degree of satisfaction with Agaricus blazei mushroom KA21 for promoting the health of senior dogs and cats among veterinarians and pet owners, Toei Shinyaku
A survey was conducted with veterinarians and pet owners concerning the degree of satisfaction with the effects of Agaricus blazei mushroom, KA21 strain as a supplement for pets (dogs and cats), for improvement of the appetite, coat & amount of fur, and amount of exercise among senior dogs and cats. The survey found that the degree of satisfaction was in the range of 86.5 - 94.4 percent among the veterinarians and 85.7 - 94.7 percent among the owners. Agaricus blazei, KA21 strain product also being sold as a supplement for pets within Japan, and is supported by many veterinarians...
Aug 11, 2022 23:45 ET
Toei Shinyaku Acquires Patent for Measurement Method of Beta-glucan, a Main Ingredient of Agaricus blazei mushroom
Through its research on Agaricus blazei, KA21 strain, Toei Shinyaku has established a measurement method for beta-glucan, one of the main ingredients of Agaricus blazei. In light of this achievement, we acquired a patent for Japan. As the manufacturer of Agaricus blazei, Toei Shinyaku has conducted research on Agaricus blazei, KA21 strain for over 25 years and presented 32 international papers on its findings; making it the company with the greatest research results out of all Japanese Agaricus blazei manufacturers....
Aug 11, 2022 23:30 ET
Announcement of Agaricus blazei mushroom, KA21 strain’s Ability to Improve QOL of Athletes at Annual Meeting, Toei Shinyaku
Toei Shinyaku gave an academic presentation regarding Agaricus blazei KA21 strain’s ability to improve QOL of athletes at the 22nd Annual Meeting of the Japanese Society of Anti-Aging Medicine. Human clinical trials confirmed the effects of Agaricus blazei KA21 strain on athlete performance, overall condition, quality of sleep, sense of fatigue, mental condition, concentration ability, muscle condition, stamina, and resilience....
Aug 11, 2022 22:15 ET
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification ...
Aug 11, 2022 22:02 ET
BBQ HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BBQ Holdings, Inc. - BBQ
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BBQ Holdings, Inc. (NasdaqGS: BBQ) to MTY Food Group Inc. (TSX: MTY). Under the terms of the proposed transaction, shareholders of BBQ will receive only $17.25 for each share of BBQ that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company....
Aug 11, 2022 22:00 ET
Study into the Satisfaction Level of Veterinarians Regarding the Effects of Agaricus blazei mushroom, KA21 supplement on Dogs / Cats Malassezia and Dermatophytosis, Toei Shinyaku
Toei Shinyaku conducted a survey to determine the effectiveness and veterinarian satisfaction level of Agaricus blazei KA21 supplement on Malassezia and dermatophytosis, and published the findings. The satisfaction level of veterinarians regarding the effects of Agaricus blazei, KA21 strain as a pet (cat/dog) supplement to treat itchiness, odor, hair loss, etc. due to mycosis was between 80.6 and 93.1%....
Aug 11, 2022 21:54 ET
Farmers Edge Reports Second Quarter 2022 Results
Farmers Edge Inc. (“Farmers Edge” or the “Company”) (TSX: FDGE), a pure-play digital agriculture company reports its financial results for the three months and six months ended June 30, 2022. All amounts are expressed in Canadian dollars. Certain metrics are non-GAAP and other financial measures or key performance indicators. See “Key Performance Indicators and Non-GAAP and Other Financial Measures” below....
Aug 11, 2022 21:53 ET
Launch of an Agaricus blazei mushroom, KA21 supplement Cross-Border EC Website, Toei Shinyaku
Toei Shinyaku has launched a cross-border EC website for Agaricus blazei, KA21 supplement. Customers from around the world have been purchasing Toei Shinyaku products for some time now; including products containing Agaricus blazei, KA21 for boosting immunity, hair growth, dieting, and improvement of the intestinal environment. We have also sold pet supplements, etc. to meet individual requests. Now all of these products can be directly purchased from our new website
Aug 11, 2022 21:53 ET
Stonepeak to Acquire Portfolio of Globe Telecom Towers in the Philippines
Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets, today announced that certain of its associated investment vehicles have signed definitive agreements to acquire 2,180 telecom towers and related passive infrastructure from Globe Telecom, Inc. (Globe) (PSE: GLO) for a total consideration of approximately $472.2 million USD (P26.2 billion). Stonepeak is entering into the transaction through Miescor Infrastructure Development Corporation (MIDC), a joint venture between Meralco Industrial Engineering Services Corporation (MIESCOR) and Stonepeak. MIESC...
Aug 11, 2022 21:52 ET
PROFESSIONAL HOLDING CORP. INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Professional Holding Corp.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Professional Holding Corp. (“Professional”) (NasdaqGS: PFHD) to Seacoast Banking Corporation of Florida (NasdaqGS: SBCF). Under the terms of the proposed transaction, shareholders of Professional will receive 0.8909 shares of Seacoast for each share of Professional that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company....
Aug 11, 2022 21:50 ET
LIFESTANCE HEALTH SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 11, 2022 to file lead plaintiff applications in a securities class action lawsuit against LifeStance Health Group, Inc. (NasdaqGS: LFST), if they purchased or acquired the Company’s Class A common stock pursuant and/or traceable to the Company’s June 2021 initial public offering (the “IPO”). This action is pending in the United States District Court for the Southern District of New York....
Aug 11, 2022 21:49 ET
CARLOTZ INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CarLotz, Inc. - LOTZ
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CarLotz, Inc. (NasdaqGM: LOTZ) to Shift Technologies, Inc. (NasdaqCM: SFT). Under the terms of the proposed transaction, shareholders of CarLotz will receive approximately 0.692158 shares of Shift for each share of CarLotz that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company....
Aug 11, 2022 21:00 ET
AVAYA ALERT: Bragar Eagel & Squire, P.C. is Investigating Avaya Holdings Corp. on Behalf of Avaya Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Avaya Holdings Corp. (“Avaya” or the “Company”) (NYSE: AVYA) on behalf of Avaya stockholders. Our investigation concerns whether Avaya has violated the federal securities laws and/or engaged in other unlawful business practices....
Aug 11, 2022 21:00 ET
COUPANG ALERT: Bragar Eagel & Squire, P.C. is Investigating Coupang, Inc. on Behalf of Coupang Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Coupang, Inc. (“Coupang” or the “Company”) (NYSE: CPNG) on behalf of Coupang stockholders. Our investigation concerns whether Coupang has violated the federal securities laws and/or engaged in other unlawful business practices....
Aug 11, 2022 21:00 ET
CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CytoDyn, Inc. (“CytoDyn” or the “Company”) (OTCMKTS: CYDY) on behalf of CytoDyn stockholders. Our investigation concerns whether CytoDyn has violated the federal securities laws and/or engaged in other unlawful business practices....
Aug 11, 2022 21:00 ET
LIFESTANCE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against LifeStance Health Group, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (NASDAQ: LFST) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired LifeStance securities pursuant to the Company’s June 11, 2021 IPO (the “Class Period”). Investors have until October 11, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit....
Aug 11, 2022 21:00 ET
RBC ALERT: Bragar Eagel & Squire, P.C. is Investigating RBC Bearings Incorporated on Behalf of RBC Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against RBC Bearings Incorporated (“RBC” or the “Company”) (NASDAQ: ROLL) on behalf of RBC stockholders. Our investigation concerns whether RBC has violated the federal securities laws and/or engaged in other unlawful business practices....